These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 19503814

  • 1. Nucleocytoplasmic shuttling activity of ataxin-3.
    Macedo-Ribeiro S, Cortes L, Maciel P, Carvalho AL.
    PLoS One; 2009 Jun 08; 4(6):e5834. PubMed ID: 19503814
    [Abstract] [Full Text] [Related]

  • 2. Proteotoxic stress increases nuclear localization of ataxin-3.
    Reina CP, Zhong X, Pittman RN.
    Hum Mol Genet; 2010 Jan 15; 19(2):235-49. PubMed ID: 19843543
    [Abstract] [Full Text] [Related]

  • 3. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
    Matos CA, de Macedo-Ribeiro S, Carvalho AL.
    Prog Neurobiol; 2011 Sep 15; 95(1):26-48. PubMed ID: 21740957
    [Abstract] [Full Text] [Related]

  • 4. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
    Chai Y, Koppenhafer SL, Shoesmith SJ, Perez MK, Paulson HL.
    Hum Mol Genet; 1999 Apr 15; 8(4):673-82. PubMed ID: 10072437
    [Abstract] [Full Text] [Related]

  • 5. Nuclear aggregation of polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic quality control.
    Breuer P, Haacke A, Evert BO, Wüllner U.
    J Biol Chem; 2010 Feb 26; 285(9):6532-7. PubMed ID: 20064935
    [Abstract] [Full Text] [Related]

  • 6. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients.
    Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G, Laccone F, Klockgether T, Völpel M, Epplen JT, Schöls L, Riess O.
    Brain Pathol; 1998 Oct 26; 8(4):669-79. PubMed ID: 9804376
    [Abstract] [Full Text] [Related]

  • 7. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM, Tran HD, Zalachoras I, Pepers BA, Meijer OC, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, van Roon-Mom WM.
    Neurobiol Dis; 2013 Oct 26; 58():49-56. PubMed ID: 23659897
    [Abstract] [Full Text] [Related]

  • 8. Identification and functional dissection of localization signals within ataxin-3.
    Antony PM, Mäntele S, Mollenkopf P, Boy J, Kehlenbach RH, Riess O, Schmidt T.
    Neurobiol Dis; 2009 Nov 26; 36(2):280-92. PubMed ID: 19660550
    [Abstract] [Full Text] [Related]

  • 9. Nucleo-cytoplasmic shuttling of Id2, a negative regulator of basic helix-loop-helix transcription factors.
    Kurooka H, Yokota Y.
    J Biol Chem; 2005 Feb 11; 280(6):4313-20. PubMed ID: 15563451
    [Abstract] [Full Text] [Related]

  • 10. KPNB1 modulates the Machado-Joseph disease protein ataxin-3 through activation of the mitochondrial protease CLPP.
    Abeditashi M, Weber JJ, Pereira Sena P, Velic A, Kalimeri M, Incebacak Eltemur RD, Schmidt J, Hübener-Schmid J, Hauser S, Macek B, Riess O, Schmidt T.
    Cell Mol Life Sci; 2022 Jul 06; 79(8):401. PubMed ID: 35794401
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
    Bichelmeier U, Schmidt T, Hübener J, Boy J, Rüttiger L, Häbig K, Poths S, Bonin M, Knipper M, Schmidt WJ, Wilbertz J, Wolburg H, Laccone F, Riess O.
    J Neurosci; 2007 Jul 11; 27(28):7418-28. PubMed ID: 17626202
    [Abstract] [Full Text] [Related]

  • 13. Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3.
    Laço MN, Cortes L, Travis SM, Paulson HL, Rego AC.
    PLoS One; 2012 Jul 11; 7(9):e43563. PubMed ID: 22970133
    [Abstract] [Full Text] [Related]

  • 14. Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation.
    Nozaki K, Onodera O, Takano H, Tsuji S.
    Neuroreport; 2001 Oct 29; 12(15):3357-64. PubMed ID: 11711886
    [Abstract] [Full Text] [Related]

  • 15. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.
    Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, Doerr J, Ladewig J, Mertens J, Tüting T, Hoffmann P, Klockgether T, Evert BO, Wüllner U, Brüstle O.
    Nature; 2011 Nov 23; 480(7378):543-6. PubMed ID: 22113611
    [Abstract] [Full Text] [Related]

  • 16. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
    Alves S, Nascimento-Ferreira I, Dufour N, Hassig R, Auregan G, Nóbrega C, Brouillet E, Hantraye P, Pedroso de Lima MC, Déglon N, de Almeida LP.
    Hum Mol Genet; 2010 Jun 15; 19(12):2380-94. PubMed ID: 20308049
    [Abstract] [Full Text] [Related]

  • 17. Nuclear-cytoplasmic shuttling of a RING-IBR protein RBCK1 and its functional interaction with nuclear body proteins.
    Tatematsu K, Yoshimoto N, Koyanagi T, Tokunaga C, Tachibana T, Yoneda Y, Yoshida M, Okajima T, Tanizawa K, Kuroda S.
    J Biol Chem; 2005 Jun 17; 280(24):22937-44. PubMed ID: 15833741
    [Abstract] [Full Text] [Related]

  • 18. Aggregation of polyglutamine-expanded ataxin-3 sequesters its specific interacting partners into inclusions: implication in a loss-of-function pathology.
    Yang H, Li JJ, Liu S, Zhao J, Jiang YJ, Song AX, Hu HY.
    Sci Rep; 2014 Sep 18; 4():6410. PubMed ID: 25231079
    [Abstract] [Full Text] [Related]

  • 19. Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix.
    Perez MK, Paulson HL, Pittman RN.
    Hum Mol Genet; 1999 Dec 18; 8(13):2377-85. PubMed ID: 10556285
    [Abstract] [Full Text] [Related]

  • 20. RNA association and nucleocytoplasmic shuttling by ataxin-1.
    Irwin S, Vandelft M, Pinchev D, Howell JL, Graczyk J, Orr HT, Truant R.
    J Cell Sci; 2005 Jan 01; 118(Pt 1):233-42. PubMed ID: 15615787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.